We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Indian drugmaker Cipla has announced that it is to launch a novel treatment
for symptoms of osteoarthritis and rheumatoid arthritis in India, to be known
as Mobix.
The multinational drug sector continues to await India's patent
law reform, which could substantially boost the companies' local research activities
and product offerings on implementation.
Israeli generic drugmaker Teva has lost its appeal against
a US court ruling denying the company 180 days' exclusivity on a generic version
of Pfizer's antidepressant Zoloft (sertaline).
According to Brazilian drug regulator Anvisa, a presidential
decree is expected to take effect within the next few weeks allowing pharmacies
to sell drugs at the exact prescribed dose, often splitting packets into several
batches of pills at the time of sale.
According to local sources, Poland's healthcare spending in 2004 was among the
lowest in Europe, at 4.3% of GDP, representing a fall of 0.6% on 1996 levels.
According to local reports, India's new excise duty regime is widely expected
to favour the country's larger local drugmakers, while imposing significant
challenges on smaller producers.
The local unit of UK- and Sweden-based drugmaker
AstraZeneca has begun construction on a new process R&D centre in India,
adjacent to the company's existing research facility in Bangalore.
Groups representing Nigerian health sector workers and officials have cited
a number of potential obstacles to the successful implementation of the country's
new health insurance scheme.